



Second Quarter 2021 Financial Results and Business Update Conference Call

Karim Mikhail
President & CEO

Michael Kalb
CFO

August 5, 2021



Forward-Looking Statements

This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA[®] (VAZKEPA in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, patent litigation, generic product launch, intellectual property, cash flow, research and development, and other statements that are forward-looking in nature and depend upon or refer to future events or conditions, including financial guidance and milestones. These statements involve known and unknown risks, uncertainties and other factors that can cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only as of the presentation date of this presentation. Please refer to the “Risk Factors” section in Amarin’s most recent Forms 10-K and 10-Q filed with the SEC and cautionary statements outlined in recent press releases for more complete descriptions of risks in an investment in Amarin.

This presentation is intended for communication with investors and not for drug promotion.

AMARIN, VASCEPA, VAZKEPA and REDUCE-IT are trademarks of Amarin Pharmaceuticals Ireland Limited. VAZKEPA is a registered trademark in Europe and other countries and regions and is pending registration in the United States.

CV Drug Development: *A Challenging Endeavor*


- Many biopharma abandoned drug development in CV
- Requirements for long-term outcomes studies evaluating thousands of patients take years to fulfill
- Significant costs to fund the commercial infrastructure needed for broad primary care reach




Amarin: *Succeeding in a Challenging Environment*

- With REDUCE-IT[®], developed the first and only approved medication for reducing cardiovascular risk beyond LDL lowering therapies in high-risk, statin treated, patients
- Launched in U.S. amidst global pandemic; achieved ~\$610 million in revenue in launch year of CVRR indication
- Country launch plans underway in Europe
- Go-to-market strategy enhances reach via orchestrated omnichannel engagement

Second Quarter Financial Highlights



- Total revenue of \$154.5 million, compared with \$135.3 million in Q2'20
- Bulk of revenue from U.S. VASCEPA sales
- U.S. VASCEPA franchise is profitable
- \$523.1 million in cash and no debt
- Strong balance sheet to support growth and expansion plans.



Source: IQVIA SMART, Jan 1992 - Dec 2011; Symphony PHAST, Jan 2010 - Jun, 2021
 Statin Brands included are Pravachol, Zocor, Lipitor, Crestor

Physicians

Payors



Pharmacists

Patients

Engaging
Effectively and
Efficiently,
with All Four Key
Stakeholders on
the U.S. Market
to *defend and grow*
VASCEPA

1st

and only approved medication to reduce

the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk¹

~50M

people in the European

Union (EU) with CV disease²

10+

years of market exclusivity in Europe




VAZKEPA in Europe: *A Significant Market Opportunity*

- Filed first 4 of 10 market access dossiers
- 5th file ready for submission and launch in Germany in September
- German launch event led by KOLs before audience of ~200 German physicians with streaming to potentially thousands across Europe
- German launch following ESC congress where VAZKEPA will be featured in multiple clinical and scientific sessions
- Dynamic go-to-market strategy includes significant digital initiatives to efficiently enhance and expand customer engagement
- Plans to implement next wave of 10 market access dossiers


1) <https://ec.europa.eu/health/documents/community-register/html/h1524.htm>

2) <http://www.ehnheart.org/cvd-statistics.html>

Amarin Future Growth Strategy



Quarterly History of Total Net Revenue



Amarin: An Exciting Opportunity to Create Value

U.S.

- Grow and defend VASCEPA despite generics' presence on the market for the VHTG indication
- Transform our go-to-market model to drive greater awareness and demand

EU

- Value based proposed list price of €200 or \$240 monthly
- Build awareness of VAZKEPA across EU as we prepare for strong sequenced launch in key markets

RoW

- Bring CV benefits of VASCEPA to 20 additional markets internationally
- Initiate the regulatory processes in several countries in coming months

Future

- Seek partnerships and opportunities to leverage growing global commercial infrastructure and competent R&D team

Q&A

